UNSPSC 51191565: Sitalidone

This classification denotes a diuretic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 06H9KWB6IB. European Medicines Agency schedules Sitalidone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10540MIG. Sitalidone generally arises in the molecular formula C23H29CLN2O5S. The term SITALIDONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, no. 3, 1989, list 29.) Most nations schedule sitalidone under HS 29350090 and SITC 51580.

As of Q4 2014, SITALIDONE remains the US FDA Preferred Term for this commodity. Sitalidone bears US NLM identifiers UMLS ID C2699304 and NCI Concept Code C74251. SMILES: CLC1C(S(=O)(=O)NC2CC(C(C)C)C(O)C(C(C)C)C2)CC(C2(O)N(C(=O)CC2)C)CC1.

UNSPSC 51191565 Sitalidone is a Commodity code representing pharmaceutical and chemical supply products for state and local government operations. Recent solicitations under this code show divergent applications: municipal water treatment facilities procuring specific industrial chemicals like sodium bisulfite, and state cooperative purchasing alliances sourcing generic pharmaceuticals and over-the-counter products for distribution across government healthcare facilities. The code encompasses both single-chemical industrial supply and multi-product pharmaceutical distribution agreements, reflecting the breadth of chemical and drug commodities state and local bodies purchase for operational and healthcare purposes.

Issuing bodies include municipal utilities (the City of Meriden, Connecticut), state procurement offices, and state cooperative purchasing alliances (MMCAP, administered by the Minnesota Department of Administration's Office of State Procurement). Geographic activity centers on the Upper Midwest and Northeast, with MMCAP's multistate pharmaceutical RFP drawing participation from Minnesota and Oregon. Representative recent opportunities include the City of Meriden's IFB for sodium bisulfite chemical supply for its Water Pollution Control Facility (due July 29, 2026) and MMCAP's RFP to establish multiple contracts for generic pharmaceuticals and OTC products across participating state and local government facilities (due March 26, 2026, with awarded vendors to become available to authorized wholesalers by May 15, 2026). Vendors responding to pharmaceutical contracts must certify compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, maintain relationships with authorized wholesalers, and carry commercial general liability insurance of $5,000,000 per occurrence; suppliers to municipal utilities must carry General Liability of $1,000,000 to $2,000,000 and provide performance and payment bonds.